Dana-Farber Cancer Institute

NIH partners with 11 biopharmaceutical companies on cancer immunotherapy strategies

Friday, October 13, 2017

The NIH and 11 biopharmaceutical companies launched the Partnership for Accelerating Cancer Therapies (PACT), a five-year public-private research collaboration totaling $215 million as part of the Cancer Moonshot. PACT will initially focus on efforts to identify, develop and validate robust biomarkers—standardized biological markers of disease and treatment response—to advance new immunotherapy treatments that harness the immune system to attack cancer. The partnership will be managed by the Foundation for the National Institutes of Health (FNIH), with the Food and Drug Administration serving in an advisory role. 

[Read More]

Initial results from Dana-Farber Cancer Institute personalized neoantigen vaccine published

Friday, July 7, 2017

Neon Therapeutics, an immuno-oncology company developing neoantigen-based therapeutic vaccines and T cell therapies to treat cancer, has announced the publication of an article in Nature presenting initial feasibility, safety, immunogenicity and clinical outcomes for a personalized neoantigen vaccine in patients with adjuvant melanoma. The article entitled ‘An immunogenic personal neoantigen vaccine for patients with melanoma’ (DOI 10.1038/nature22991) demonstrates the validity of the neoantigen vaccine approach as an effective immunotherapy.

[Read More]

The Institute for Protein Innovation launches

Friday, May 12, 2017

A team of scientists from the Massachusetts biomedical community launched a new research institute to expand protein science and enhance drug discovery. Backed by a unique and collaborative combination of public investment and academic philanthropy, The Institute for Protein Innovation (IPI) brings together leaders in academic research, biotechnology, pharmaceuticals and biomedical investing to seek new therapies for currently intractable diseases. 

[Read More]

Spotlight Innovation appoints Chitra Edwin SVP of Regulatory Affairs and Compliance

Thursday, December 8, 2016

Spotlight Innovation, a pharmaceutical company advancing technologies designed to address rare, emerging and neglected diseases, has announced the appointment of Chitra Edwin, Ph.D., RAC, as senior vice president of Regulatory Affairs and Compliance. Dr. Edwin will provide leadership for all U.S. and international regulatory matters including strategic planning for regulatory approvals, preparation of regulatory submissions, serving as the primary contact with the FDA and other regulatory authorities, and ensuring compliance with regulatory requirements.

[Read More]

Schulman IRB’s Central Oncology Review Division adds Judith Carrithers

Tuesday, October 4, 2016

Schulman IRB, a central IRB in customer service and technology, announced that Judith Carrithers, JD, MPA, will join its Central Oncology Review (COR) division October 15, 2016, as director of Oncology Services. Launching later in 2016, COR will provide collaborative, flexible IRB review services for oncology research centers seeking a more advanced level of partnership and service integration from a central IRB. [Read More]

2016 Lasker Awards honor scientists for basic and clinical medical research

Monday, September 26, 2016

The Albert and Mary Lasker Foundation has announced the winners of the 2016 Lasker Awards for medical science: William G. Kaelin, Peter J. Ratcliffe, and Gregg L. Semenza for basic medical research;Ralf F.W. Bartenschlager, Charles M. Rice, and Michael J. Sofia for clinical research; and Bruce M. Alberts for special achievement. The 2016 Lasker Awards, which carry an honorarium of $250,000 for each category, will be presented on Friday, September 23, in New York City.

[Read More]

C4 Therapeutics completes core scientific leadership team

Wednesday, September 7, 2016

C4 Therapeutics (C4T) has announced details of the leadership team recruited to develop a new class of broadly applicable small molecule drugs for degrading disease-relevant proteins for therapeutic benefit. The leadership team includes Isabel Chiu, Ph.D., as senior vice president of Translational Sciences and Alliance Management, Stewart Fisher, Ph.D., as senior vice president of Discovery Sciences, Tim Heffernan, Ph.D., as senior vice president of Biology, and Christopher Nasveschuk, Ph.D., as vice president of Chemistry.

[Read More]

Orchard Therapeutics launches, partners on transformative gene therapies

Monday, May 9, 2016

Orchard Therapeutics, a clinical-stage biotechnology company with operations in London and the U.S., has officially launched with a £21-million Series A financing led by F-Prime Capital. As part of its launch, the company has announced formal partnerships with University College London (UCL), Great Ormond Street Hospital for Children NHS Foundation Trust (GOSH), the University of Manchester, the University of California Los Angeles (UCLA) and Boston Children’s Hospital for the development of transformative gene therapies for serious and life-threatening orphan diseases.

[Read More]

Collaborative Cancer Cloud expands to drive medicines to patients faster

Monday, April 11, 2016

The Dana-Farber Cancer Institute (DFCI) of Boston and the Ontario Institute for Cancer Research (OICR) in Toronto have joined the Collaborative Cancer Cloud, a partnership formed in August 2015 by the Knight Cancer Institute at Oregon Health and Science University (OHSU) of Portland, Oregon, and Intel. By allowing research institutions to securely share genomic, imaging and clinical data on a precision medical analytics platform, the Collaborative Cancer Cloud is positioning itself to make rapid strides in cancer research and lifesaving therapies.

[Read More]